BeOne Medicines Ltd. (ONC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ONC scores 71 out of 100 (letter grade B-; verdict "Roarable Buy — Sound Institutional Accumulation"). The five pillars are:

• Fundamental Cash Engine (16/20): Per the RQD rating, this reflects ROIC of 10.5% and an FCF yield of 2.23%. Upside driver: the company's cash generation is positive on the reported FCF figures. Valuation tradeoff: a 2.23% FCF yield is a thin cash return relative to a 147.2x trailing P/E.
• Whale 13F Flow (14/20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying 13F holder data is not itemized in the source data (see Analyst View section), so the score cannot be traced to specific filings here.
• Insider Conviction (9/20): Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest pillar; the underlying transaction records are not provided in the source data.
• Macro Regime Fit (14/20): Per the RQD rating, beta is 0.98 and the score reflects sector sensitivity. A beta near 1.0 implies the stock has historically moved roughly in line with the market; the sector-sensitivity inputs are not itemized in the source data.
• Forensic Balance Sheet (18/20): Per the RQD rating, Altman Z is 6.68, Piotroski F is 9/9, and Debt/Equity is 0.22. This is the strongest pillar and the main support for the rating's durability.

Investor implications: the rating combines a strong balance sheet and positive recent cash flow with a valuation that is very high on earnings multiples (P/E TTM 147.2, Forward P/E 123.6, EV/EBITDA 63.9). Upside depends on earnings growth converting into the multiples; the weakest pillar (insider conviction) provides the least confirmation from insiders. This is an educational reading of the scores, not a recommendation.

BeOne Medicines Ltd. (ONC) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it operates with a market capitalization of $42.2B. The source data does not describe its products, customers, or revenue model beyond the sector and industry classification.

Per the market data, gross margin is 87.5%, operating margin 8.4%, and net margin 5.4%. ROIC is 10.5%. Per the RQD rating, the Altman Z-Score is 6.68 and the Piotroski F-Score is 9/9. Per the financials, FY 2025 shows a swing to positive operating income and net income after losses in FY 2023 and FY 2024, with year-end cash of $4547.5M against debt of $961.9M; the FY 2023 cash figure is not available in source data.

• Positive catalysts (GREEN): A Yahoo Finance item headlined that ONC surged on strong financial performance and upgraded guidance; an Investor's Business Daily item references visions of 177% earnings growth; a Yahoo Finance item references a rating upgrade to Strong Buy.
• Neutral/market wire (YELLOW): A Seeking Alpha item discusses Brukinsa and Tevimbra facing a high bar; a Simply Wall St item covers stock forecasts and analyst predictions.
• Risk watch (RED): A MarketBeat item reports the stock fell 5.8%.
• Proprietary signals: None in the Butterfly graph.

The news items are headline-level only; the source data does not contain the article bodies, so the underlying claims cannot be verified beyond their headlines.

• What are the specific revenue drivers and products behind the FY 2025 revenue figure of $5343.0M, and what share is concentrated in the named brands (Brukinsa, Tevimbra) referenced in the news?
• What is the basis for the 177% earnings growth figure, and does it reconcile with the trailing EPS of 2.52 and the reported FY 2025 net income of $286.9M?
• What was FY 2023 cash, and what drove the swing from FY 2024 losses to FY 2025 positive operating income?
• Who are the 13F holders and insiders underlying the Whale (14/20) and Insider (9/20) pillar scores?
• What is the eventual dilution, EPS, and EPS-per-share context behind the EPS field being reported as N/A for all periods?